HK1258447A1 - 非選擇性代謝型谷氨酸受體激活劑用於治療注意缺陷病症和22q綜合症 - Google Patents

非選擇性代謝型谷氨酸受體激活劑用於治療注意缺陷病症和22q綜合症

Info

Publication number: HK1258447A1
Authority: HK; Hong Kong
Prior art keywords: syndrome; treatment; attention deficit; glutamate receptor; metabotropic glutamate
Prior art date: 2015-09-08

Application number

HK19100752.7A

Other languages

English (en)

Inventor

Hakon Hakonarson

Charlly Kao

Original Assignee

Childrens Hospital Philadelphia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-08

Filing date

2019-01-16

Publication date

2019-11-15

2019-01-16 Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia

2019-11-15 Publication of HK1258447A1 publication Critical patent/HK1258447A1/zh

Links

208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title 1
102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
239000012190 activator Substances 0.000 title 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 title 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 title 1
208000011580 syndromic disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pathology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HK19100752.7A 2015-09-08 2019-01-16 非選擇性代謝型谷氨酸受體激活劑用於治療注意缺陷病症和22q綜合症 HK1258447A1 (zh)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562215673P	2015-09-08	2015-09-08
US201562215633P	2015-09-08	2015-09-08
US201562215636P	2015-09-08	2015-09-08
US201562215628P	2015-09-08	2015-09-08
PCT/US2016/050559 WO2017044491A1 (en)	2015-09-08	2016-09-07	Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome

Publications (1)

Publication Number	Publication Date
HK1258447A1 true HK1258447A1 (zh)	2019-11-15

Family

ID=56943962

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
HK19100753.6A HK1258448A1 (zh)	2015-09-08	2019-01-16	診斷和治療行為障礙的方法
HK19100745.7A HK1258373A1 (zh)	2015-09-08	2019-01-16	診斷和治療圖雷特多綜合症的方法
HK19100751.8A HK1258446A1 (zh)	2015-09-08	2019-01-16	診斷和治療焦慮症的方法
HK19100752.7A HK1258447A1 (zh)	2015-09-08	2019-01-16	非選擇性代謝型谷氨酸受體激活劑用於治療注意缺陷病症和22q綜合症

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
HK19100753.6A HK1258448A1 (zh)	2015-09-08	2019-01-16	診斷和治療行為障礙的方法
HK19100745.7A HK1258373A1 (zh)	2015-09-08	2019-01-16	診斷和治療圖雷特多綜合症的方法
HK19100751.8A HK1258446A1 (zh)	2015-09-08	2019-01-16	診斷和治療焦慮症的方法

Country Status (13)

Country	Link
US (12)	US9884057B2 (zh)
EP (9)	EP4023222A1 (zh)
JP (8)	JP7281280B2 (zh)
CN (7)	CN116919961A (zh)
AU (8)	AU2016318786B2 (zh)
CA (5)	CA2997187C (zh)
DK (4)	DK3347016T3 (zh)
ES (5)	ES2909329T3 (zh)
HK (4)	HK1258448A1 (zh)
IL (10)	IL300474A (zh)
PL (2)	PL3977996T3 (zh)
SG (1)	SG10202012842SA (zh)
WO (4)	WO2017044491A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012027491A1 (en)	2010-08-24	2012-03-01	The Children's Hospital Of Philadelphia	Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same
CN116919961A (zh) *	2015-09-08	2023-10-24	费城儿童医院	诊断和治疗焦虑症的方法
WO2017210502A1 (en) *	2016-06-03	2017-12-07	Yale University	Methods and apparatus for predicting depression treatment outcomes
US10918632B2 (en) *	2016-09-07	2021-02-16	The Children's Hospital Of Philadelphia	Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
US11684617B2 (en)	2017-04-19	2023-06-27	The Children's Hospital Of Philadelphia	Methods of diagnosing and treating ADHD in biomarker positive subjects
WO2018209328A1 (en) *	2017-05-11	2018-11-15	Miwa Julie M	Compositions and methods for treating lynx2 disorders
CN107483425B (zh) *	2017-08-08	2020-12-18	北京盛华安信息技术有限公司	基于攻击链的复合攻击检测方法
SG11202006790XA (en)	2018-01-18	2020-08-28	Childrens Hospital Philadelphia	Solid forms of fasoracetam
US11535604B2 (en)	2018-01-18	2022-12-27	The Children's Hospital Of Philadelphia	Fasoracetam crystalline forms
KR102250063B1 (ko) *	2019-06-14	2021-05-12	한국생명공학연구원	뚜렛증후군의 원인 유전자를 동정하는 방법
CN110955751A (zh) *	2019-11-13	2020-04-03	广州供电局有限公司	工作票文本去重方法、装置、***及计算机存储介质
MX2023003258A (es) *	2020-09-21	2023-05-08	Reveragen Biopharma Inc	Tratamiento de enfermedades mediadas por nf-kb.
WO2022065518A1 (ja) *	2020-09-23	2022-03-31	国立大学法人京都大学	神経突起伸長促進剤
CN117594119B (zh) *	2024-01-17	2024-05-10	北京大学第六医院	用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040116505A1 (en) *	2001-02-23	2004-06-17	Gregory Krauss	Treatment of tics, tremors and related disorders
US20050233321A1 (en)	2001-12-20	2005-10-20	Hess John W	Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
EP1729751A1 (en)	2004-03-25	2006-12-13	Smithkline Beecham Corporation	Use of an nk3 antagonist for the treatment of bipolar disorders
US20070244143A1 (en)	2006-03-08	2007-10-18	Braincells, Inc	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) *	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
TW200819458A (en)	2006-06-23	2008-05-01	Merz Pharma Gmbh & Co Kgaa	Metabotropic glutamate receptor modulators
US20100120628A1 (en)	2007-02-06	2010-05-13	Genizon Biosciences Inc.	Genemap of the human genes associated with adhd
EP2149047A4 (en)	2007-04-30	2010-05-19	Univ Ohio State Res Found	POLYMORPHISMS IN GENES WITH INFLUENCE ON DOPAMINTRANSPORTER DISEASES AND ITS APPLICATIONS
US20090176740A1 (en)	2007-11-30	2009-07-09	Phillips Ii Dauglas James	Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
CA2716375C (en)	2008-02-20	2018-05-29	The Children's Hospital Of Philadelphia	Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
US20110311512A1 (en)	2008-11-14	2011-12-22	Hakon Hakonarson	Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets
WO2010057132A1 (en)	2008-11-14	2010-05-20	The Children's Hospital Of Philadelphia	Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same
WO2011022312A1 (en) *	2009-08-20	2011-02-24	Merck Sharp & Dohme Corp.	Ether benzotriazole derivatives
US8714471B2 (en) *	2010-07-29	2014-05-06	Brady Worldwide, Inc.	Friction core brake
WO2012027491A1 (en) *	2010-08-24	2012-03-01	The Children's Hospital Of Philadelphia	Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same
US20130225623A1 (en)	2010-10-27	2013-08-29	Mount Sinai School Of Medicine	Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
WO2016022324A1 (en)	2014-05-30	2016-02-11	The Children's Hospital Of Philadelphia	Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism
US20140315992A1 (en)	2011-07-07	2014-10-23	The Children's Hospital Of Philadelphia	Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013305580A1 (en) *	2012-08-23	2015-04-09	Stuart L. Weg	Anxiolytic composition, formulation and method of use
US9346239B2 (en)	2012-09-26	2016-05-24	Eastman Kodak Company	Method for providing patterns of functional materials
WO2014152965A2 (en)	2013-03-14	2014-09-25	The Children's Hospital Of Philadelphia	Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
US11219617B2 (en)	2014-05-30	2022-01-11	The Children's Hospital Of Philadelphia	Methods of diagnosing and treating autism
KR102232583B1 (ko)	2015-01-08	2021-03-26	삼성전자주식회사	전자장치 및 전자장치의 웹 재현 방법
EP3307913A4 (en)	2015-06-15	2019-03-27	The Children's Hospital of Philadelphia	METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM
CN116919961A (zh)	2015-09-08	2023-10-24	费城儿童医院	诊断和治疗焦虑症的方法

2016
- 2016-09-07 CN CN202310713811.5A patent/CN116919961A/zh active Pending
- 2016-09-07 DK DK16771034.2T patent/DK3347016T3/da active
- 2016-09-07 WO PCT/US2016/050559 patent/WO2017044491A1/en active Application Filing
- 2016-09-07 EP EP22156141.8A patent/EP4023222A1/en active Pending
- 2016-09-07 WO PCT/US2016/050580 patent/WO2017044502A1/en active Application Filing
- 2016-09-07 US US15/258,828 patent/US9884057B2/en active Active
- 2016-09-07 DK DK16767114.8T patent/DK3347014T3/da active
- 2016-09-07 JP JP2018512296A patent/JP7281280B2/ja active Active
- 2016-09-07 CA CA2997187A patent/CA2997187C/en active Active
- 2016-09-07 SG SG10202012842SA patent/SG10202012842SA/en unknown
- 2016-09-07 JP JP2018512234A patent/JP7152306B2/ja active Active
- 2016-09-07 EP EP16771034.2A patent/EP3347016B1/en active Active
- 2016-09-07 JP JP2018512235A patent/JP7027308B2/ja active Active
- 2016-09-07 ES ES16767112T patent/ES2909329T3/es active Active
- 2016-09-07 EP EP24153857.8A patent/EP4342493A3/en active Pending
- 2016-09-07 CA CA2997188A patent/CA2997188A1/en active Pending
- 2016-09-07 JP JP2018512253A patent/JP7281279B2/ja active Active
- 2016-09-07 US US15/258,924 patent/US20170087139A1/en not_active Abandoned
- 2016-09-07 AU AU2016318786A patent/AU2016318786B2/en active Active
- 2016-09-07 CA CA2997189A patent/CA2997189A1/en active Pending
- 2016-09-07 CN CN201680065041.6A patent/CN108495630A/zh active Pending
- 2016-09-07 CN CN201680065071.7A patent/CN108601776A/zh active Pending
- 2016-09-07 EP EP16767112.2A patent/EP3347013B1/en active Active
- 2016-09-07 ES ES21170586T patent/ES2976071T3/es active Active
- 2016-09-07 ES ES16767114T patent/ES2897953T3/es active Active
- 2016-09-07 CN CN202211219188.XA patent/CN115919852A/zh active Pending
- 2016-09-07 US US15/258,969 patent/US11179378B2/en active Active
- 2016-09-07 PL PL21201628.1T patent/PL3977996T3/pl unknown
- 2016-09-07 EP EP21201653.9A patent/EP3964213B1/en active Active
- 2016-09-07 US US15/258,977 patent/US11173153B2/en active Active
- 2016-09-07 ES ES16767115T patent/ES2898932T3/es active Active
- 2016-09-07 CA CA3225374A patent/CA3225374A1/en active Pending
- 2016-09-07 EP EP21170586.8A patent/EP3922249B1/en active Active
- 2016-09-07 IL IL300474A patent/IL300474A/en unknown
- 2016-09-07 DK DK16767115.5T patent/DK3347015T3/da active
- 2016-09-07 CN CN202310713998.9A patent/CN116919962A/zh active Pending
- 2016-09-07 IL IL303605A patent/IL303605A/en unknown
- 2016-09-07 EP EP21201628.1A patent/EP3977996B1/en active Active
- 2016-09-07 PL PL21201653.9T patent/PL3964213T3/pl unknown
- 2016-09-07 WO PCT/US2016/050581 patent/WO2017044503A1/en active Application Filing
- 2016-09-07 CN CN201680065080.6A patent/CN108348518A/zh active Pending
- 2016-09-07 AU AU2016318780A patent/AU2016318780B2/en active Active
- 2016-09-07 AU AU2016318775A patent/AU2016318775B2/en active Active
- 2016-09-07 CN CN201680065020.4A patent/CN108348517B/zh active Active
- 2016-09-07 EP EP16767115.5A patent/EP3347015B1/en active Active
- 2016-09-07 IL IL290993A patent/IL290993B2/en unknown
- 2016-09-07 WO PCT/US2016/050573 patent/WO2017044497A1/en active Application Filing
- 2016-09-07 DK DK16767112.2T patent/DK3347013T3/da active
- 2016-09-07 CA CA2997191A patent/CA2997191A1/en active Pending
- 2016-09-07 EP EP16767114.8A patent/EP3347014B1/en active Active
- 2016-09-07 AU AU2016318785A patent/AU2016318785B2/en active Active
- 2016-09-07 ES ES16771034T patent/ES2876898T3/es active Active
2017
- 2017-12-21 US US15/850,307 patent/US10869861B2/en active Active
2018
- 2018-02-26 IL IL257744A patent/IL257744B/en unknown
- 2018-02-26 IL IL257747A patent/IL257747B/en unknown
- 2018-02-26 IL IL257746A patent/IL257746B/en unknown
- 2018-02-28 IL IL257785A patent/IL257785B/en unknown
2019
- 2019-01-16 HK HK19100753.6A patent/HK1258448A1/zh unknown
- 2019-01-16 HK HK19100745.7A patent/HK1258373A1/zh unknown
- 2019-01-16 HK HK19100751.8A patent/HK1258446A1/zh unknown
- 2019-01-16 HK HK19100752.7A patent/HK1258447A1/zh unknown
2020
- 2020-03-04 US US16/809,045 patent/US11298347B2/en active Active
- 2020-12-17 US US17/125,164 patent/US20210205288A1/en active Pending
2021
- 2021-10-27 US US17/511,795 patent/US11806340B2/en active Active
- 2021-10-28 US US17/512,827 patent/US11806341B2/en active Active
2022
- 2022-02-16 JP JP2022022123A patent/JP2022078104A/ja active Pending
- 2022-02-28 IL IL290994A patent/IL290994A/en unknown
- 2022-02-28 IL IL290985A patent/IL290985A/en unknown
- 2022-02-28 IL IL290992A patent/IL290992B2/en unknown
- 2022-04-06 US US17/714,276 patent/US20220296582A1/en active Pending
- 2022-05-05 AU AU2022203039A patent/AU2022203039A1/en active Pending
- 2022-06-20 AU AU2022204324A patent/AU2022204324A1/en active Pending
- 2022-06-21 AU AU2022204355A patent/AU2022204355A1/en active Pending
- 2022-07-11 AU AU2022205142A patent/AU2022205142A1/en active Pending
- 2022-09-29 JP JP2022155714A patent/JP2023011558A/ja active Pending
- 2022-12-09 JP JP2022197117A patent/JP2023051937A/ja active Pending
- 2022-12-09 JP JP2022197128A patent/JP2023036671A/ja active Pending
2023
- 2023-10-30 US US18/497,338 patent/US20240100036A1/en active Pending
- 2023-10-30 US US18/497,386 patent/US20240075022A1/en active Pending

Also Published As

Publication number	Publication date
IL290993B2 (en)	2023-11-01
IL257747B (en)	2022-04-01
SG10202012842SA (en)	2021-01-28
EP4342493A2 (en)	2024-03-27
IL300474A (en)	2023-04-01
AU2016318785A1 (en)	2018-04-12
JP2023011558A (ja)	2023-01-24
IL290992B1 (en)	2023-03-01
US11298347B2 (en)	2022-04-12
WO2017044491A1 (en)	2017-03-16
JP2018526398A (ja)	2018-09-13
US20170087140A1 (en)	2017-03-30
US20220117953A1 (en)	2022-04-21
IL257746A (en)	2018-06-28
CN108348517A (zh)	2018-07-31
HK1258373A1 (zh)	2019-11-08
EP3347016B1 (en)	2021-04-28
JP2022078104A (ja)	2022-05-24
EP3347015A1 (en)	2018-07-18
AU2022205142A1 (en)	2022-07-28
EP3977996B1 (en)	2024-03-13
CN108348518A (zh)	2018-07-31
CN108601776A (zh)	2018-09-28
CA2997188A1 (en)	2017-03-16
AU2016318780A1 (en)	2018-04-12
EP4023222A1 (en)	2022-07-06
CA2997191A1 (en)	2017-03-16
EP3347016A1 (en)	2018-07-18
US20170087141A1 (en)	2017-03-30
ES2898932T3 (es)	2022-03-09
ES2876898T3 (es)	2021-11-15
EP3964213B1 (en)	2024-03-13
ES2909329T3 (es)	2022-05-06
JP7281280B2 (ja)	2023-05-25
IL257747A (en)	2018-06-28
JP7281279B2 (ja)	2023-05-25
JP2023051937A (ja)	2023-04-11
WO2017044503A1 (en)	2017-03-16
AU2016318780B2 (en)	2022-04-07
AU2022203039A1 (en)	2022-05-26
HK1258448A1 (zh)	2019-11-15
HK1258446A1 (zh)	2019-11-15
US11806340B2 (en)	2023-11-07
WO2017044502A1 (en)	2017-03-16
EP3347015B1 (en)	2021-10-20
AU2016318785B2 (en)	2022-04-14
AU2016318786A1 (en)	2018-04-12
US20240100036A1 (en)	2024-03-28
CA2997189A1 (en)	2017-03-16
EP4342493A3 (en)	2024-07-03
US11173153B2 (en)	2021-11-16
EP3347013B1 (en)	2022-02-16
US20210205288A1 (en)	2021-07-08
IL290985A (en)	2022-05-01
EP3347014B1 (en)	2021-10-20
US20170105985A1 (en)	2017-04-20
CA2997187C (en)	2024-02-20
IL290993A (en)	2022-05-01
IL257744B (en)	2022-04-01
DK3347014T3 (da)	2021-12-06
IL257746B (en)	2022-04-01
ES2976071T3 (es)	2024-07-22
ES2897953T3 (es)	2022-03-03
JP7027308B2 (ja)	2022-03-01
IL290993B1 (en)	2023-07-01
US20240075022A1 (en)	2024-03-07
JP2018526396A (ja)	2018-09-13
EP3964213A1 (en)	2022-03-09
IL290992A (en)	2022-05-01
EP3922249B1 (en)	2024-02-28
US20180110767A1 (en)	2018-04-26
IL290992B2 (en)	2023-07-01
US11806341B2 (en)	2023-11-07
AU2016318775A1 (en)	2018-04-12
EP3977996A1 (en)	2022-04-06
AU2016318775B2 (en)	2022-02-10
US20220117954A1 (en)	2022-04-21
US20170087139A1 (en)	2017-03-30
AU2022204355A1 (en)	2022-07-14
DK3347016T3 (da)	2021-07-12
AU2016318786B2 (en)	2022-04-07
EP3347014A1 (en)	2018-07-18
US9884057B2 (en)	2018-02-06
CN108495630A (zh)	2018-09-04
PL3977996T3 (pl)	2024-07-01
IL257744A (en)	2018-06-28
CA2997187A1 (en)	2017-03-16
IL257785B (en)	2022-04-01
AU2022204324A1 (en)	2022-07-07
IL257785A (en)	2018-06-28
DK3347015T3 (da)	2021-12-06
PL3964213T3 (pl)	2024-07-08
JP7152306B2 (ja)	2022-10-12
IL303605A (en)	2023-08-01
DK3347013T3 (da)	2022-04-04
EP3922249A1 (en)	2021-12-15
IL290994A (en)	2022-05-01
JP2018526394A (ja)	2018-09-13
CN116919962A (zh)	2023-10-24
EP3347013A1 (en)	2018-07-18
US20200306237A1 (en)	2020-10-01
CN108348517B (zh)	2021-11-05
CA3225374A1 (en)	2017-03-16
JP2018526395A (ja)	2018-09-13
US20220296582A1 (en)	2022-09-22
US11179378B2 (en)	2021-11-23
WO2017044497A1 (en)	2017-03-16
CN116919961A (zh)	2023-10-24
US10869861B2 (en)	2020-12-22
CN115919852A (zh)	2023-04-07
JP2023036671A (ja)	2023-03-14

Publication	Publication Date	Title
IL290992A (en)	2022-05-01	Non-selective metabotropic glutamate receptor activators for the treatment of ADHD and 22q syndrome
IL250436A0 (en)	2017-03-30	Medical pad systems and methods
DK3386484T3 (da)	2022-07-04	Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
GB2537970B (en)	2022-03-30	Shade adjustment notification system and method
IL248757B2 (en)	2023-03-01	Controllable drug delivery system and method of use
GB201802952D0 (en)	2018-04-11	Itinerary generation and adjustment system
HK1215119A1 (zh)	2016-08-12	治療產品遞送系統和配對方法
HK1212791A1 (zh)	2016-06-17	可動態組合和調整的個人工作系統
HUE052709T2 (hu)	2021-05-28	Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
PT3160964T (pt)	2024-06-07	Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos
HK1244429A1 (zh)	2018-08-10	特別用於治療注意力缺陷障礙的方法和組合物
EP3216242C0 (en)	2023-12-27	NOTIFICATION OF SUSPENSION OF AN EMBMS SESSION
DK3113782T3 (da)	2022-10-17	Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin
IL267205B (en)	2022-10-01	Inhibited waxy starches and methods of using them
ZA201702403B (en)	2018-08-29	Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
FI20146023A (fi)	2016-05-22	Hammas- ja kielituki
HK1259078A1 (zh)	2019-11-22	合成的鞘脂類分子、藥物、它們的合成方法及治療方法
IL249894A0 (en)	2017-03-30	Targeted medical nanoparticles and methods for their preparation and use
IL264165A (en)	2019-02-28	Inhibited starches, coagulation retarders and methods of using them
PL3288483T3 (pl)	2021-02-08	System kotwienia i pozycjonowania czaszkowego
GB201411150D0 (en)	2014-08-06	Novel aptamers and therapeutic uses thereof
GB2531711B (en)	2016-09-28	Authentication system and method of authentication
GB201615010D0 (en)	2016-10-19	Delayed-gelling, inhibited starches and methods of using them
GB2529144B (en)	2017-02-22	Adjustable track system and method of configuring same
GB2522731B (en)	2016-04-13	Balustrade fixing device, balustrade and method of fixing